Simon Holton

Title: Simon Holton: Innovator in Antibody Development

Introduction

Simon Holton is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 17 patents to his name, Holton's work has the potential to impact cancer treatment and other medical conditions.

Latest Patents

One of Holton's latest patents focuses on Anti-CEACAM6 antibodies and their uses. This invention provides recombinant antigen-binding regions and antibodies that are specific for human CEACAM6, a molecule associated with various cancers. The antibodies developed through this invention do not significantly cross-react with closely related human CEACAM proteins, making them a targeted therapeutic option. Additionally, the invention includes methods for generating these antibodies, as well as nucleic acid sequences, vectors, pharmaceutical compositions, and kits for their use.

Career Highlights

Throughout his career, Simon Holton has worked with notable companies in the pharmaceutical industry, including Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH. His experience in these organizations has allowed him to refine his expertise in antibody development and intellectual property management.

Collaborations

Holton has collaborated with esteemed colleagues such as Hans Briem and Gerhard Siemeister. These partnerships have contributed to the advancement of his research and the successful development of innovative therapeutic solutions.

Conclusion

Simon Holton's contributions to the field of biotechnology, particularly in the development of targeted antibodies, highlight his role as a leading inventor. His work continues to pave the way for advancements in cancer treatment and other medical applications.